… Phosphodiesterase type 5 inhibitors (PDE5Is), due to their efficacy and tolerable profile for
more than 2 decades,are considered a good … Oral PDE5Is have in general stimulatory effects …

… Nowadays, Oral phosphodiesterase type 5 inhibitors (PDE5Is) … Currently, four oral PDE5Is
have been approved by the US … , and avanafil with good efficacy and bearable adverse effects. …

… mechanism that explain the favorable effects of PDE5 inhibitors in these patients. Sildenafil
citrate use has been verified to exhibit protective effects in pulmonary arterial hypertension …

… Currently, oral phosphodiesterase type 5 inhibitors (PDE5Is) are the first-line therapy for
ED. However, they are effective in all treated cases with variable non-responsiveness. Many …

… enzyme, researchers have looked into further non-erectogenic and non-hypertensive uses …
are also multidrug resistance transporter inhibitors, it is possible that they will be helpful in the …

… effects. Common pharmacological agents that are used to enhance PE and also modulate
cardiovascular function include phosphodiesterase Type 5 (PDE-5) inhibitors (PDE-5i)… benefit […

… , PDE5 inhibitors would be of most benefit to these patients, as modulation of NO availability
has the potential to counteract the adverse effects of pulmonary microangiopathy [98]. …

… Phosphodiesterase type 5 inhibitors restore nitric oxide signaling, that plays a significant role
in … beneficial effects of PDE-5 inhibitors on ED in patients with type 2 diabetes (T2D) [7, 8]. …

… Phosphodiesterase type 5 (PDE5) inhibitors are considered to play a role in increasing …
Avanafil is the only selective inhibitor of the PDE5 isoenzyme with a low frequency of side effects …